TransGenic Group

TransGenic Group Deferred Tax Liabilities

The Deferred Tax Liabilities of TransGenic Group (2342.T) as of Nov 11, 2026 is 12.92 M JPY. In the previous year, Deferred Tax Liabilities was 5.85 M JPY — a change of 120.80% (higher).

Deferred Tax Liabilities

12.92 MJPY

YoY

120.80%

Last updated:

Deferred Tax Liabilities of TransGenic Group is 2025 12.92 M JPY. Deferred Tax Liabilities of TransGenic Group was 2024 5.85 M JPY. It decreases by 120.80% higher compared to the previous year.

The TransGenic Group Deferred Tax Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Deferred Tax Liabilities
Date
Deferred Tax Liabilities
Jan 1, 2015
0.00 JPY
Jan 1, 2016
976,000.00 JPY
Jan 1, 2018
5.85 M JPY
Jan 1, 2025
12.92 M JPY
The TransGenic Group Deferred Tax Liabilities history
YEARDeferred Tax LiabilitiesYoY
12.92 MJPY+120.80%
5.85 MJPY+499.59%
976,000.00JPY—
0.00JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

TransGenic Group Stock analysis

What does TransGenic Group do? TransGenic Group Inc. generates revenue through three business segments. The Contract Research Organization (CRO) segment provides contract clinical tests for pharmaceuticals and foods, including pharmacodynamic and safety pharmacology tests, as well as non-clinical safety tests for pesticides and food. It also offers contract production of genetically modified mice and antibodies, sales of model mice, and development of new biomarkers. The Diagnostic Analysis segment delivers pathological diagnosis services, gene analysis contract services, and drug discovery support for individualized medicine. The TGBS segment provides business succession and revitalization advice and support services, alongside an electronic commerce (EC) business for retail and wholesale of electrical products. The CRO segment serves pharmaceutical and food companies requiring clinical and non-clinical testing services. The Diagnostic Analysis segment targets healthcare providers and researchers needing diagnostic and drug discovery support. The TGBS segment caters to businesses seeking succession planning and revitalization services, while its EC business sells electrical products to retail and wholesale customers. Revenue streams include fees from clinical and safety testing, production of genetically modified animals, sales of model mice, and development of biomarkers under the CRO segment. The Diagnostic Analysis segment earns from pathology services, gene analysis, and drug discovery support. The TGBS segment generates income through advisory services and EC sales of electrical products. TransGenic Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TransGenic Group stock

Deferred Tax Liabilities of TransGenic Group is 12.92 M JPY in 2025.

Deferred Tax Liabilities of TransGenic Group changed from 5.85 M JPY to 12.92 M JPY, representing a 120.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Deferred Tax Liabilities TransGenic Group since 2006 – with annual values, charts, and detailed analysis.

Deferred tax liabilities arise from temporary differences between accounting and tax treatments. They represent taxes owed in the future on income already recognized.

Deferred Tax Liabilities's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Deferred Tax Liabilities's TransGenic Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — TransGenic Group

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — TransGenic Group